Literature DB >> 30188536

Live bacterial biotherapeutics in the clinic.

Luis G Bermúdez-Humarán1, Philippe Langella1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30188536     DOI： 10.1038/nbt.4248

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  12 in total

1.  Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-β1 under the control of dietary xylan 1.

Authors:  Zaed Z R Hamady; Nigel Scott; Mark D Farrar; Meenu Wadhwa; Paula Dilger; Terence R Whitehead; Robin Thorpe; Keith T Holland; J Peter A Lodge; Simon R Carding
Journal:  Inflamm Bowel Dis       Date:  2010-12-17       Impact factor: 5.325

2.  A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation.

Authors:  Rose A Whelan; Sebastian Rausch; Friederike Ebner; Dorothee Günzel; Jan F Richter; Nina A Hering; Jörg-Dieter Schulzke; Anja A Kühl; Ahmed Keles; Pawel Janczyk; Karsten Nöckler; Lothar H Wieler; Susanne Hartmann
Journal:  Mol Ther       Date:  2014-07-02       Impact factor: 11.454

3.  Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease.

Authors:  E Quévrain; M A Maubert; C Michon; H Sokol; P Seksik; F Chain; R Marquant; J Tailhades; S Miquel; L Carlier; L G Bermúdez-Humarán; B Pigneur; O Lequin; P Kharrat; G Thomas; D Rainteau; C Aubry; N Breyner; C Afonso; S Lavielle; J-P Grill; G Chassaing; J M Chatel; G Trugnan; R Xavier; P Langella
Journal:  Gut       Date:  2015-06-04       Impact factor: 23.059

4.  Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy.

Authors:  Sewanti Atul Limaye; Robert I Haddad; Fiona Cilli; Stephen T Sonis; A Dimitrios Colevas; Michael T Brennan; Kenneth S Hu; Barbara A Murphy
Journal:  Cancer       Date:  2013-09-24       Impact factor: 6.860

5.  A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice.

Authors:  Hubert Plovier; Amandine Everard; Céline Druart; Clara Depommier; Matthias Van Hul; Lucie Geurts; Julien Chilloux; Noora Ottman; Thibaut Duparc; Laeticia Lichtenstein; Antonis Myridakis; Nathalie M Delzenne; Judith Klievink; Arnab Bhattacharjee; Kees C H van der Ark; Steven Aalvink; Laurent O Martinez; Marc-Emmanuel Dumas; Dominique Maiter; Audrey Loumaye; Michel P Hermans; Jean-Paul Thissen; Clara Belzer; Willem M de Vos; Patrice D Cani
Journal:  Nat Med       Date:  2016-11-28       Impact factor: 53.440

6.  Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.

Authors:  Zhongyi Chen; Lilu Guo; Yongqin Zhang; Rosemary L Walzem; Julie S Pendergast; Richard L Printz; Lindsey C Morris; Elena Matafonova; Xavier Stien; Li Kang; Denis Coulon; Owen P McGuinness; Kevin D Niswender; Sean S Davies
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

7.  Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus.

Authors:  L A Lagenaur; B E Sanders-Beer; B Brichacek; R Pal; X Liu; Y Liu; R Yu; D Venzon; P P Lee; D H Hamer
Journal:  Mucosal Immunol       Date:  2011-07-06       Impact factor: 7.313

8.  Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci.

Authors:  Luis G Bermúdez-Humarán; Jean-Paul Motta; Camille Aubry; Pascale Kharrat; Laurence Rous-Martin; Jean-Michel Sallenave; Céline Deraison; Nathalie Vergnolle; Philippe Langella
Journal:  Microb Cell Fact       Date:  2015-02-26       Impact factor: 5.328

9.  Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes.

Authors:  Franklin F Duan; Joy H Liu; John C March
Journal:  Diabetes       Date:  2015-01-27       Impact factor: 9.461

10.  Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU.

Authors:  Katherine E Durrer; Michael S Allen; Ione Hunt von Herbing
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240
View more
  7 in total

1.  A Summary of the Fifth Annual Virology Education HIV Microbiome Workshop.

Authors:  Scott Sherrill-Mix; Kaleigh Connors; Grace M Aldrovandi; Jason M Brenchley; Charles Boucher; Frederic D Bushman; Ronald G Collman; Satya Dandekar; Nichole R Klatt; Laurel A Lagenaur; Roger Paredes; Gilda Tachedjian; Jim A Turpin; Alan L Landay; Mimi Ghosh
Journal:  AIDS Res Hum Retroviruses       Date:  2020-09-07       Impact factor: 2.205

2.  A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota.

Authors:  Yusook Chung; Yongku Ryu; Byung Chull An; Yeo-Sang Yoon; Oksik Choi; Tai Yeub Kim; Jaekyung Yoon; Jun Young Ahn; Ho Jin Park; Soon-Kyeong Kwon; Jihyun F Kim; Myung Jun Chung
Journal:  Microbiome       Date:  2021-05-26       Impact factor: 14.650

3.  Production and Sensing of Butyrate in a Probiotic Escherichia coli Strain.

Authors:  Yanfen Bai; Thomas J Mansell
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

4.  Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and co-morbidities.

Authors:  Kenneth Timmis; James Kenneth Timmis; Harald Brüssow; Luis Ángel Fernández
Journal:  Microb Biotechnol       Date:  2019-01       Impact factor: 5.813

5.  Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy.

Authors:  Amin Zargar; Samantha Chang; Ankita Kothari; Antoine M Snijders; Jian-Hua Mao; Jessica Wang; Amanda C Hernández; Jay D Keasling; Trever G Bivona
Journal:  Chronic Dis Transl Med       Date:  2020-01-08

Review 6.  Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease.

Authors:  Bei Yue; Zhi-Lun Yu; Cheng Lv; Xiao-Long Geng; Zheng-Tao Wang; Wei Dou
Journal:  World J Gastroenterol       Date:  2020-08-14       Impact factor: 5.742

7.  Primary Human Dendritic Cells and Whole-Blood Based Assays to Evaluate Immuno-Modulatory Properties of Heat-Killed Commensal Bacteria.

Authors:  James E Norton; Sushma Kommineni; Patricia Akrivoulis; Dario A Gutierrez; Daria J Hazuda; Gokul Swaminathan
Journal:  Vaccines (Basel)       Date:  2021-03-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.